ATE522510T1 - Fluoreszierende pyrazin-derivate und verwendungsverfahren dafür bei der überprüfung der nierenfunktion - Google Patents

Fluoreszierende pyrazin-derivate und verwendungsverfahren dafür bei der überprüfung der nierenfunktion

Info

Publication number
ATE522510T1
ATE522510T1 AT07013568T AT07013568T ATE522510T1 AT E522510 T1 ATE522510 T1 AT E522510T1 AT 07013568 T AT07013568 T AT 07013568T AT 07013568 T AT07013568 T AT 07013568T AT E522510 T1 ATE522510 T1 AT E522510T1
Authority
AT
Austria
Prior art keywords
derivative
spectral energy
pyrazine derivatives
formulas
checking
Prior art date
Application number
AT07013568T
Other languages
English (en)
Inventor
Raghavan Rajagopalan
William L Neumann
Richard B Dorshow
Dennis A Moore
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of ATE522510T1 publication Critical patent/ATE522510T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/08Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
    • B01J2219/12Processes employing electromagnetic waves
    • B01J2219/1203Incoherent waves
    • B01J2219/1206Microwaves

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
AT07013568T 2004-12-23 2005-12-22 Fluoreszierende pyrazin-derivate und verwendungsverfahren dafür bei der überprüfung der nierenfunktion ATE522510T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63861104P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
ATE522510T1 true ATE522510T1 (de) 2011-09-15

Family

ID=36570361

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05855315T ATE466000T1 (de) 2004-12-23 2005-12-22 Fluoreszente pyrazinderivate und verfahren zu deren anwendung bei der bewertung der nierenfunktion
AT07013568T ATE522510T1 (de) 2004-12-23 2005-12-22 Fluoreszierende pyrazin-derivate und verwendungsverfahren dafür bei der überprüfung der nierenfunktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05855315T ATE466000T1 (de) 2004-12-23 2005-12-22 Fluoreszente pyrazinderivate und verfahren zu deren anwendung bei der bewertung der nierenfunktion

Country Status (11)

Country Link
US (5) US8778309B2 (de)
EP (4) EP1836175B1 (de)
JP (1) JP2008525487A (de)
CN (2) CN101087767A (de)
AT (2) ATE466000T1 (de)
AU (1) AU2005322114A1 (de)
CA (1) CA2592021A1 (de)
DE (1) DE602005020981D1 (de)
ES (2) ES2375395T3 (de)
IL (1) IL183962A0 (de)
WO (1) WO2006071759A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149479A1 (en) 2006-06-22 2007-12-27 Mallinckrodt Inc. Pyrazine derivatives and uses thereof in renal monitoring
ATE466000T1 (de) 2004-12-23 2010-05-15 Mallinckrodt Inc Fluoreszente pyrazinderivate und verfahren zu deren anwendung bei der bewertung der nierenfunktion
CA2616147A1 (en) 2006-02-24 2007-09-20 Mallinckrodt Inc. Process for using optical agents
JP2009541323A (ja) * 2006-06-22 2009-11-26 マリンクロット インコーポレイテッド 拡張された共役を有するピラジン誘導体およびその使用
CN101687040A (zh) 2007-03-01 2010-03-31 马林克罗特公司 整合光活性的小分子及其用途
CA2641297A1 (en) * 2008-07-11 2010-01-11 Richard B. Dorshow Pyrazine derivatives, methods of use, and methods for preparing same
WO2010121003A1 (en) 2009-04-16 2010-10-21 Mallinckrodt Inc. Pyrazine derivatives for optical imaging and therapy
US9433700B2 (en) 2009-04-27 2016-09-06 Medibeacon Inc. Tissue sealant compositions, vascular closure devices, and uses thereof
WO2011031955A2 (en) * 2009-09-11 2011-03-17 Mallinckrodt Inc. Optical monitoring of leukemia
DE102011012674B3 (de) * 2011-02-28 2012-04-26 Ldiamon As Verfahren und Nachweisvorrichtung zur Bestimmung eines Nierenfunktionsparameters
US11077211B2 (en) * 2013-11-11 2021-08-03 Medibeacon Inc. Compositions and methods for assessing gut function
US10858359B2 (en) 2016-06-07 2020-12-08 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic ring derivatives useful as SHP2 inhibitors
CN109983001B (zh) 2016-07-12 2023-04-04 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
CN106543089A (zh) * 2016-11-04 2017-03-29 山东铂源药业有限公司 一种达沙替尼中间体的合成方法
TWI820013B (zh) 2017-01-23 2023-11-01 美商銳新醫藥公司 作為別構shp2抑制劑之雙環化合物
JP7240320B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としてのピリジン化合物
KR102306048B1 (ko) 2017-01-30 2021-09-29 메디비콘 아이엔씨. 확산 반사 보정을 갖는 형광 추적제의 비침습 모니터링 방법
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
EP3694848A1 (de) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridin-, pyrazin- und triazinverbindungen als allosterische shp2-inhibitoren
KR20220003659A (ko) * 2017-10-27 2022-01-10 메디비콘 아이엔씨. 신장 기능 측정을 위한 조성물 및 시스템
EP3700579A4 (de) * 2017-10-27 2021-07-21 MediBeacon Inc. Verfahren zur bestimmung der renalen funktion
SG11201909366XA (en) 2017-11-20 2019-11-28 Medibeacon Inc Method for preparing and analyzing fluorescent compounds in plasma
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
US11261165B2 (en) 2019-01-16 2022-03-01 Medibeacon Inc. Two piece sensor assembly and method of use
KR20210124295A (ko) 2019-01-28 2021-10-14 메디비콘 아이엔씨. 가정용 경피 gfr 모니터링을 위한 시스템 및 방법
CN110144050B (zh) * 2019-06-28 2021-06-29 西北大学 一种具有MnO4-检测功能的稀土铕配位聚合物及其制备方法
JP2022551501A (ja) 2019-10-10 2022-12-09 メディビーコン,インク. 5-アミノウラシルの陽極酸化
US20240025864A1 (en) * 2020-11-09 2024-01-25 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Method for preparing 3,6-diaminopyrazine-2,5-dicarboxylic acid and synthetic intermediate thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948895A (en) 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
IL39114A0 (en) * 1971-04-13 1972-05-30 Du Pont Novel cyanopyrazines carbamoyl diaminopyrazines,and 3,5-diaminopyrazinoic acid,and their preparation
US3814757A (en) 1971-04-13 1974-06-04 Du Pont Diamino substituted dicyano pyrazines and process
US3808209A (en) * 1972-07-14 1974-04-30 Du Pont Tetraaminopyrazine,2,3,5-triamino-6-nitropyrazine,2,6-diamino-3,5-dinitropyrazine
US4517186A (en) * 1982-09-30 1985-05-14 Merck & Co., Inc. 2-Amino-3,5-dicyano-6-(substituted)pyrazine antimicrobial compounds
DE3768479D1 (de) 1986-08-13 1991-04-11 Nippon Soda Co 2,3-diaminoacrylonitrilderivate.
JPH0249775A (ja) 1988-05-19 1990-02-20 Nippon Soda Co Ltd 6員環又は7員環を有する複素環化合物及びその製造方法
JPH0217163A (ja) 1988-07-05 1990-01-22 Nippon Soda Co Ltd ジアミノマレオニトリル及びジアミノアクリロニトリル誘導体の製造方法
JPH0269457A (ja) 1988-09-06 1990-03-08 Nippon Soda Co Ltd ピロール誘導体及びその製造法
US5145610A (en) * 1989-11-27 1992-09-08 E. I. Du Pont De Nemours And Company Organic optical elements and nonlinear optical devices
JPH04112877A (ja) 1990-09-04 1992-04-14 Nippon Soda Co Ltd 新規シアノピラジン誘導体及びその製造方法
EP0579835A4 (en) * 1991-11-12 1994-06-01 Nippon Soda Co Wavelength conversion material for agriculture
JPH07149736A (ja) * 1993-10-07 1995-06-13 Nippon Soda Co Ltd シアノピラジン誘導体および成形体
JPH07278456A (ja) * 1994-04-12 1995-10-24 Nippon Soda Co Ltd 蛍光着色剤
JPH09143168A (ja) 1995-11-22 1997-06-03 Nippon Soda Co Ltd 2,3−ジアミノアクリロニトリル誘導体および3,6−ジアミノ−2,5−ピラジンジカルボニトリルの製造方法
JP3845848B2 (ja) 1996-01-25 2006-11-15 日本曹達株式会社 2,3−ジアミノアクリロニトリル誘導体の製造方法
JPH09249773A (ja) * 1996-03-19 1997-09-22 Nippon Soda Co Ltd 波長変換能を有するポリオレフィン系樹脂組成物、その組成物用マスターバッチおよびその組成物を含む農業用フイルム
JP3986587B2 (ja) * 1996-07-30 2007-10-03 日本曹達株式会社 ピラジンジカルボン酸誘導体及びその製造方法
US5928625A (en) * 1997-03-13 1999-07-27 Mallinckrodt Inc. Method of measuring physiological function
JP4153060B2 (ja) 1997-09-25 2008-09-17 日本曹達株式会社 ピラジン環を主鎖に有するポリエステル系化合物、その製造方法および高分子色素
JP2002523405A (ja) 1998-08-20 2002-07-30 アボット・ラボラトリーズ レジオ選択的置換ピラジン異性体を製造するための方法
US6440389B1 (en) 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
US6733744B1 (en) * 2000-10-16 2004-05-11 Mallinckrodt Inc. Indole compounds as minimally invasive physiological function monitoring agents
US7556797B2 (en) * 2000-10-16 2009-07-07 Mallinckrodt Inc. Minimally invasive physiological function monitoring agents
EP1355640A1 (de) 2001-01-23 2003-10-29 Neurosearch A/S Verwendung von nicht kompetitiven und selektiven glur5-antagonisten als modulierende verbindungen des glutamatrezeptors
JP4112877B2 (ja) 2001-03-09 2008-07-02 ダイセル化学工業株式会社 環状イミド系化合物で構成された触媒、及びこの触媒を用いた有機化合物の製造法
ATE466000T1 (de) 2004-12-23 2010-05-15 Mallinckrodt Inc Fluoreszente pyrazinderivate und verfahren zu deren anwendung bei der bewertung der nierenfunktion

Also Published As

Publication number Publication date
JP2008525487A (ja) 2008-07-17
US20140039191A1 (en) 2014-02-06
US20220127237A1 (en) 2022-04-28
AU2005322114A1 (en) 2006-07-06
WO2006071759A2 (en) 2006-07-06
US10617687B2 (en) 2020-04-14
CN101812027A (zh) 2010-08-25
US9376399B2 (en) 2016-06-28
DE602005020981D1 (de) 2010-06-10
US20090010851A1 (en) 2009-01-08
CA2592021A1 (en) 2006-07-06
ATE466000T1 (de) 2010-05-15
ES2345209T3 (es) 2010-09-17
EP1854790B1 (de) 2011-08-31
WO2006071759A3 (en) 2006-09-14
US20160280665A1 (en) 2016-09-29
EP1854790A1 (de) 2007-11-14
IL183962A0 (en) 2007-10-31
CN101087767A (zh) 2007-12-12
EP1836175A2 (de) 2007-09-26
US20170298030A9 (en) 2017-10-19
EP1836175B1 (de) 2010-04-28
US20160280666A1 (en) 2016-09-29
ES2375395T3 (es) 2012-02-29
EP2135863A1 (de) 2009-12-23
EP2039688A1 (de) 2009-03-25
US8778309B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
ATE522510T1 (de) Fluoreszierende pyrazin-derivate und verwendungsverfahren dafür bei der überprüfung der nierenfunktion
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
ATE373665T1 (de) Benzo-kondensierte heteroarylamid-derivative von thienopyridinen nützlich als therapeutische agentien, entsprechende pharmazeutische zusammensetzungen, und methoden für ihre verwendung
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
ATE464299T1 (de) Neues phenylalaninderivat
ATE193453T1 (de) Nicht-invasive feststellung der integration eines transgens bei säugetieren
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
ATE557026T1 (de) Vasopressin v1a antagonisten
AR045161A1 (es) Derivados de quinazolina
BR9914044A (pt) ésteres tetrahidropirido
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
DE60123461D1 (de) Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel
MXPA04000793A (es) Novedoso metodo terapeutico.
DE69828964D1 (de) Aromatische maleimide und ihre verwendung als photoinitiatoren
CY1114364T1 (el) Φαρμακευτικες συνθεσεις για την θεραπεια της αρτηριοπαθειας των τριχοειδων αγγειων
DE69725457D1 (de) Piperazinderivate als neurokinin-antagonisten
EP1409482A4 (de) Farbstoff-sulfenate für die duale phototherapie
BRPI0410840A (pt) derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
DE60102151D1 (de) Neue thiochromanderivate und ihre verwendung als thrombininhibitoren
WO2003001182A3 (en) Homocysteinylated transthyretin
ATE254457T1 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
AR062200A1 (es) Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties